Epithalon

Epithalon is a linear tetrapeptide with no disulfide bridges and no terminal modifications, representing one of the smallest defined regulatory-peptide architectures studied in laboratory research. Its interaction profile in the literature centers on telomerase-activity modulation in cell-culture investigations, with downstream studies probing telomere-length dynamics in aging-related pathway research. The molecule's small size and simple architecture make it an interesting reference standard in structure-activity studies probing the minimal sequence requirements for regulatory-peptide activity. Pharmacokinetic descriptors documented in published animal-model investigations include rapid plasma clearance and short systemic residence under standard parenteral paradigms. All activity descriptors here are framed as documented in published research rather than as effects of the supplied product. Structural confirmation of supplied lots is established by mass spectrometry molecular-ion match to the C14H22N4O9 empirical formula, with HPLC-validated purity reported on each Certificate of Analysis.

Experimental domains documented in the published literature include telomerase-activity assays in cell-culture systems, telomere-length dynamics studies in aging-pathway research, pineal-axis signaling investigations, circadian-rhythm research in animal models, and structure-activity work probing the minimal sequence requirements for regulatory-peptide activity. Investigators have also characterized Epithalon in comparative studies alongside other short regulatory peptides and in screening assays for telomerase-pathway modulators. Use in laboratory research extends to mechanism-elucidation paradigms where the molecule serves as a probe for short-peptide regulatory signaling rather than as a defined intervention. The reference standard is supplied for these and equivalent in-vitro and animal-model experimental contexts only, with no associated guidance for human, clinical, or veterinary application. Researchers should consult primary literature when designing context-specific protocols.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C14H22N4O9 empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters reflect general best-practice for lyophilized peptide reference standards and do not constitute preparation guidance for human or veterinary application.